We describe a TNF fusion protein designated TNFSelectokine, which is a homo-trimeric molecule comprised of a single chain antibody (scFv) targeting module, a trimerization domain and TNF. TNFSelectokine exerts high bioactivity towards the targeted and adjacent, antigen negative cells. Membrane targeting dependent immobilization of the TNF-Selectokine induced cell death in TNFR1 and TNFR2 dependent manner, thus cell bound TNF-Selectokine mimicks membrane TNF. To restrict TNF activity to the tumor, a prototype of a TNF-Selectokine prodrug was constructed by insertion of a TNFR1 fragment, separated from TNF by a protease-sensitive linker. The prodrug exerts minimal TNF activity, but can be activated in vitro several thousand-fold by proteolytic digest, showing the principal feasibility of this approach. Choice of cleavage site(s) recognized by protease(s) typically associated with a given carcinoma should allow high dose systemic application of the respective TNF prodrug that unveils its specific bioactivity only in targeted tissues.
Introduction
The use of TNF as a widely applicable tumor therapeutic is hampered by its severe systemic toxicity, allowing successful clinical application only with isolated limb perfusion techniques Eggermont and ten Hagen, 2001 ). To overcome the problems arising from systemic TNF administration, TNF targeting by generation of complete or single chain (scFv) antibody-TNf fusion proteins (Rosenblum et al., 1995; Scherf et al., 1996; Christ et al., 2001) and by recruitment of biotinylated TNF to preformed antibody-avidin complexes (Gasparri et al., 1999) was studied in mouse tumor models, revealing an increased anti-tumoral activity. Therapeutic activity of TNF was also improved by addition of short peptide targeting sequences, as shown for the CNRGC peptide, targeting TNF to aminopeptidase N of tumor endothelial cells (Curnis et al., 2000) . Indeed, tumor endothelial cells are considered as a key target for TNF mediated induction of tumor necrosis (Ruegg et al., 1998; Nooijen et al., 1998; Stoelker et al., 2000) . They express TNFR1 and 2, which both contribute to the endothelial TNF response (Schmid et al., 1995; Stoelker et al., 2000) . Cosignaling via TNFR2, which physiologically requires the membrane form of TNF (memTNF) (Grell et al., , 1998 , can enhance tumor cell apoptosis and various other, endothelial as well as immune cell responses (for review see Wajant and Scheurich, 2001; Locksley et al., 2001) thus potentially promoting the antitumoral activity of TNF at several levels. Like tumor endothelial cells, reactive fibroblasts of the tumor stroma represent a potentially useful, because general, target that is present in the vast majority of all carcinomas. Reactive stromal fibroblasts can make up to 90% of the tumor mass, are genetically stable, surround both tumor cells and endothelial cells and selectively express high levels of fibroblast activation protein (FAP) (Garin-Chesa et al., 1990) , the latter thus serving as a unique marker for tumor stroma. Antibody mediated targeting of TNF to FAP should not only allow a high tumor enrichment of the cytokine, but also its presentation to adjacent endothelial and tumor cells in a membrane TNF like manner, i.e. with high signal capacity for both TNFRs.
The TNF domain of TNF-fusion proteins described so far is, while in circulation, capable to interact with and signal to non-targeted cells, thus at least partially blunting the selective targeting strategy and potentially resulting in significant systemic toxicity. For example, NGF-TNF displayed the same LD 50 as regular recombinant TNF (Curnis et al., 2000) . In order to prevent targeting-independent action of TNF fusion proteins, we considered a prodrug strategy in analogy to chemotherapeutic prodrug systems, which have been shown to increase drug efficacy by reducing systemic toxicity. For the activation of chemical prodrugs, tumor targeted as well as intra-tumoral enzymes have been successfully used (DeFeo-Jones et al., 2000; Huang and Oliff, 2001) . We reasoned that it should be possible to provide TNF in an inactive proform, which upon target binding, can be proteolytically processed to a bioactive, still target bound TNF. The data described here show the principal feasibility of this approach.
Results

Production of the TNF-Selectokine and the TNF-Selectokine Prodrug
The structural elements of the TNF-Selectokine and TNF-Selectokine Prodrug (shortly : prodrug) are schematically outlined in Figure 1 . Both types of constructs are homotrimeric, scFv-TNF fusion proteins covalently linked via a 30 aa coiled -coil trimerization domain derived from Tenascin without and with, respectively, a C-terminally located TNFR1 derived TNF binding domain followed by a myc-his tag for easy detection/ purification. The TNFR1 fragment in the prodrug is separated from TNF by a flexible linker module that carries several consensus cleavage sites for model proteases (see Materials and methods) to test proteolytic processing and conversion into an active TNFSelectokine. In order to avoid a potential cleavage of the TNF module from the N-terminal antibodyTenascin modules by endogeneous proteases, the cleavage site within TNF (AA 1 -12) for its natural processing enzyme TACE (Black et al., 1997) was deleted. For efficient production in mammalian cells, the vectors pDB1 (TNF-Selectokine) and pW32 (prodrug) also contain the selectable marker dihydrofolate reductase. Upon methotrexate (25 mM) dependent gene amplification, stable CHO transfectants could be established without subcloning, producing the TNF-Selectokine (DB1) and prodrug (W32) with yields of 4 -6 and 3 -5 mg/l, respectively. This material could be purified to near homogeneity by affinity chromatography (Figure 2 ). SDS -PAGE and Western-blot analysis revealed bands corresponding to a MW of approx. 190, 140 and 60 kDa for the TNFSelectokine and 210, 160 and 80 kDa for the prodrug. Under reducing conditions single bands with an apparent MW of 60 and 85 kDa were detected ( Figure  2a ), corresponding to the calculated MW of 54.1 and 69.3 kDa for the TNF-Selectokine and prodrug, respectively. Size exclusion chromatography showed that the IMAC-purified TNF-Selectokine eluted as a single peak corresponding to a MW of approximately 186 kDa (Figure 2b ).
Functional activity of the TNF-Selectokine and TNF-Selectokine Prodrug
Specific antigen binding via the scFv module was determined for both, the TNF-Selectokine and the prodrug by FACS analyses using FAP-positive transfectants, HT1080#33 (Park et al., 1999) , and FAPnegative HT1080 control cells, the latter showing no signal above background (Figure 2c 710 M for the TNF-Selectokine and the prodrug, respectively, verify specific, high affinity antigen binding for both constructs.
TNF activity of the fusion proteins was determined with the TNF sensitive, FAP-negative Kym-1 rhabdomyosarcoma cell line . Induction of (Figure 3a ). These data show (i) full bioactivity of the TNF moiety fused the scFv module and (ii) an almost four orders of magnitude lower activity of the prodrug, indicating a very efficient neutralization of TNF activity by C-terminal fusion of the extracellular TNFR1 fragment. Of note, when induction of cell death was determined in antigenpositive versus -negative HT1080 target cells, a superior activity (410 -100-fold, depending on the experiment) of the TNF-Selectokine was revealed on FAP expressing as compared to FAP-negative cells (Figure 3b ), whereas sensitivity of the two cell lines towards recombinant soluble TNF was identical.
Proteolytic activation of the TNF-Selectokine Prodrug
Short treatment of prodrug W32 with trypsin resulted in appearance of several fragments in Coomassie stained gels, with one band migrating in a size range expected from cleavage at the linker downstream of the TNF module (Figure 4a , insert). As only the undigested monomer could be detected in Western-blotting via the c-myc-specific antibody (not shown), proteolytic cleavage apparently occurred at multiple sites but always included a removal of the C-terminal tag. Analyses for the presence of bioactive TNF-Selectokine in the crude tryptic digest of the prodrug revealed a surprisingly high apoptosis inducing activity in the KYM-1 assay, with a greater than 2000-fold rise compared to the nondigested prodrug ( Figure 4a ). Appropriate controls with mock digested prodrug as well as treatment of target cells with trypsin containing buffers and neutralization by TNF specific antibodies verified that induction of cell death is mediated by the tryptically activated TNF-Selectokine (data not shown).
Activation of the TNF-Selectokine Prodrug by tissue plasminogen activator (tPA)
The demonstration of proteolytic activation of the prodrug by the rather nonselective trypsin cleavage encouraged further studies with more selective and patho-physiologically relevant proteases. The prodrug contains a linker with a consensus cleavage sites for the proteases thrombin, factor VIIa, uPA and tPA, the latter two as examples of proteases overexpressed in a number of solid tumors (Paciucci et al., 1998; De Petro et al., 1998; Aguirre-Ghiso et al., 1999) . Whereas thrombin treatment failed to process the prodrug, a partial processing was achieved by in vitro tPa digest. The appearance of a C-terminal 15 -20 kDa fragment in Western blot analyses with anti c-myc antibody (Figure 4b , insert) matches with a calculated fragment size of 18 kDa expected upon site-specific cleavage within the protease linker between the TNF and the TNFR domain. The partial tPA digest of the prodrug gave rise to a 200 -500-fold activation (Figure 4b ), indicating correct processing of the prodrug to an active TNF-Selectokine. Both biochemical data and bioassay suggest that under the applied conditions a fraction of approximately 5% of the prodrug was converted.
As negative control, incubation of the prodrug for up to 36 h at 378C in digestion buffer without tPA or buffer with fresh mouse serum (10%) showed no unspecific activation of the prodrug.
TNF-Selectokine bound to the target antigen signals cell death to adjacent cells
The (Figure 5b ), indicating that conversion of the prodrug can occur in a cell bound state. As expected from FACS analysis, FAP-negative HT1080 cells were unable to present the TNF-Selectokine to neighbouring cells (Figure 5a,b) . Together, these results show, in addition to direct action on the targeted cell, a juxtatropic TNF action.
Inducing cell death in neighboring cells by an active TNF-Selectokine is reminiscent of the action of naturally expressed memTNF, which only in this form is capable to efficiently activate TNFR2 (Grell et al., , 1998 . To assess whether the TNF-Selectokine, targeted to cell membranes via FAP-binding, has gained memTNF like activities we performed coculture assays with a human tumor target cell line (Colo205), requiring cosignaling via TNFR1 and TNFR2 for induction of cell death . The data presented in Figure 5c show that in the presence of the TNF-Selectokine Colo205 cells are killed upon coculture with FAP-positive, but not FAP-negative cells. Further, pretreatment of HT1080#33 and subsequent removal of unbound TNF-Selectokine was sufficient to induce cell death of Colo205 cells (data not shown). Clearly, these results are in accordance with an appropriate activation of both TNFRs by the targeted TNF-Selectokine.
Discussion
Efficient targeting and site specific actions of tumor therapeutics represent a major challenge in oncology, in particular for cytokine based therapeutic strategies because of their typically pleiotropic actions throughout the body. Antibody-directed targeting of cytokines is a promising first step to improve therapeutic efficacy, when structural prerequisites for assembly of monomeric subunits into functional cytokines can be reliably met. Cytokine fusion proteins, targeted by antibodydomains or other means, however, carry an active cytokine module capable of signaling before the target has been reached, and unwanted systemic side effects have still to be considered. Using TNF as a model cytokine that already proofed its clinical utility when applied locoregional under ILP conditions Eggermont and ten Hagen, 2001) , we have here experimentally tested the hypotheses of genetically engineering a cytokine prodrug that combines all necessary features of a drug with potentially engineering a cytokine prodrug that combines all necessary features of a drug with potentially selective antitumoral activities, in particular high level functional expression and stability of the prodrug by constructing a single chain molecule with intrinsic trimerization capability, good targeting function due to high affinity interaction with a tumor associated antigen, site specific activation in a cell bound state and high specific bioactivity towards targeted and juxtaposed cells.
A unique feature of the TNF-Selectokine is the presence of an intramolecular inhibitor, a TNFR1 fragment, thereby creating a prodrug. The prodrug showed the same antigen binding characteristics, which indicates that the fused TNFR domain does not interfere with this activity. The TNFR1-fragment containing the extracellular domains 1 -3 is known to bind TNF with high affinity (Corcoran et al., 1994) . The fusion of this fragment to the TNF-Selectokine inhibited TNF activity almost by four log (Figure 3 ) and its proteolytic removal allowed recovery of TNF activity (Figures 4 and 5 ). Provided these in vitro results translate to the in vivo situation, i.e. lack of unspecific activation and systemic toxicity of the prodrug, this potentially opens up a large therapeutic Eggermont and ten Hagen, 2001) , the prodrug could theoretically be applied 100-fold below its calculated MTD, yet reach effective concentrations even when only a low percentage of the prodrug is targeted and activated at the tumor site. In support of this, we show that the prodrug can be processed in vitro, with respect to TNF activity, into a fully functional molecule, subsequent to cell targeting through the antibody module via proteolytic removal of the inhibitory domain. In vitro activation of the prodrug could be achieved with a rather nonselective tryptic digest, but more relevant, was also obtained by site-specific cleavage with tPA. Accordingly, the introduction of specific cleavage sites recognized by this and other proteases frequently associated with and overexpressed in solid tumors, such as MMPs and plasminogen activating proteases (Paciucci et al., 1998; De Petro et al., 1998; Aguirre-Ghiso et al., 1999) should allow a locally restricted unmasking of TNF bioactivity in the targeted area only. The functionally silent TNF in the prodrug form should highly increase the systemically applicable dose and lead to a better tumor enrichment because of the dual feature of the TNF-Selectokine prodrug, target antigen dependent recruitment via the scFv domain and prevention of non target directed TNF signaling en route to its tumor target due to interaction with ubiquitously expressed TNFRs of normal tissues.
The TNF-Selectokine prodrug represents a prototype that can be readily modified to minimize the inhibitory fragment, e.g. by reducing the TNFR fragment to a minimal ligand interaction domain comprised of the extracellular cystein rich regions 2 and 3 (Banner et al., 1993) , or by introducing other, natural or artificial sequences mimicking TNFR binding (Takasaki et al., 1997) . Further, optimizing the linker both with respect to type of proteolytic cleavage sites and good accessibility of these sites for tumor-associated proteases is amenable and should not only enable a controlled, tumor selective processing, but also allow, by construction of selective linkers, a specific adaptation of the TNF-Selectokine to different tumor entities.
Because the trimeric organization of TNF is essential for bioactivity, a further unique feature of the TNFSelectokine is the introduction of the Tenascin domain forming a coiled-coil structure to create a linker between the single chain antibody module. This enforces the generation of a homotrimeric fusion protein, which is further stabilized by spontaneous formation of intermolecular disulphide bonds between cysteine residues of the Tenascin domain. This structural organization of the TNF-Selectokine bears several advantages: First, the four-fold increase in affinity in comparison to the parental scFv (Brooks et al., 2001) , likely due to avidity effects of the trivalent antigen binding site, indicates a greater potential of selective tumor enrichment. Second, because the size of the trimeric TNF-Selectokine is in the range of normal immunoglobulins and the covalent linkage prevents spontaneous dissociation into monomers, functional inactivation and rapid renal clearance, as known to occur for TNF at low concentrations and also reported for some of the TNF fusion proteins (Gasparri et al., 1999; Corti et al., 1992) , is precluded. Accordingly, an increased serum half-life of the TNF-Selectokine as compared to other TNF fusion proteins and TNF itself is expected. In the prodrug form, which completely lacks TNF activity up to very high concentrations, a prolonged serum half-life should not increase the risk of systemic reactions. Third, the Tenascin stabilized trimeric state of the TNF-Selectokine ensues upon targeting and proteolytic activation in a cell bound state, i.e. TNF activity is maintained independent of biophysical parameters and thus should lead to a prolonged TNF signal capacity at the site of prodrug activation in vivo.
Our in vitro studies show that, on a molar basis, active TNF-Selectokine exerted as nontargeted molecule the same specific activity as soluble recombinant TNF, indicating that the construction of a rather complex fusion protein had no negative influence on TNF function. In addition, TNF-Selectokine exhibited superior activity in a target bound state towards juxtaposed cells. The high signal capacity of activated TNF-Selectokine was evident from the coculture assays identifying the juxtatropic action: In contrast to soluble TNF, which typically needs to be present at the effective concentration for several hours in order to induce apoptosis, a decoration of target cells with the TNF-Selectokine and subsequent removal of unbound reagent was sufficient to induce cell death in added tumor cells. Of note, the observed induction of Colo205 cell death indicates that the targeted TNFSelectokine functionally differs from soluble TNF in that it is capable to activate TNFR2, i.e. mimicks membrane TNF (Grell et al., , 1998 . This juxtatropic signal capacity via both TNFRs appears of particular interest in the context of the target specificity of the antibody used here for construction of the TNF-Selectokine. The antigen recognized, FAP, is a dominant marker of stromal fibroblasts within solid tumors (Garin-Chesa et al., 1990) . Stromal cells always contribute to a significant amount to total tumor mass and are dispersed throughout tumor tissue, surrounding malignant cells and tumor vasculature (GarinChesa et al., 1990) . Stromal markers like FAP appear therefore ideal candidate targets for recruitment of therapeutics such as cytokines exerting their action not or not only on the targeted cells themselves, but also or predominantly on the surrounding cells. In the case of TNF, special emphasis is on tumor endothelial cells, considered as main target cells for TNF induced tumor necrosis (Ruegg et al., 1998; Stoelker et al., 2000) , but also infiltrating immune cells and the malignant cells alike. For all three potential target cells of TNF action at the tumor site, several previous studies have provided evidence for an important role of coactivation of both TNFRs to induce optimum responses (for review see Wajant and Scheurich, 2001; Locksley et al., 2001 ). Accordingly, a superior antitumoral activity of the TNF-Selectokine as compared to recombinant soluble TNF can be envisaged.
In conclusion, the TNF-Selectokine prodrug represents the prototype of a novel class of cytokine fusion proteins combining features that potentially allow a high degree of tumor selective action. It can be envisaged that the principle of site-specific activation will be applicable not only to other members of the TNF family but should also be adaptable to other protein therapeutics with known protein or peptide inhibitors.
Materials and methods
Cell lines
The HT1080 cell line and the stably transfected, human FAP expressing clone #33 (Park et al., 1999) were cultured in DMEM/NutMix F12 (HAM) (Life Technologies) supplemented with 10% FCS and in addition, for the FAP-positive clones, 200 mg/ml G418 (Life Technologies, Karlsruhe, Germany); the CHO DG44 a dhfr 7/7 cell line adapted to serum free conditions was cultured in cho-s-sfm II (Life Technologies, Karlsruhe, Germany). Both cell lines were kindly provided by Dr WJ Rettig (Boehringer Ingelheim Pharma KG, Biberach, Germany). Stable transfectants of CHO DG44 producing the fusion proteins DB1, W24 and W32, respectively, were established and maintained in 25 mM methotrexate containing culture medium. KYM-1 human rhabdomyosarcoma cells and the Colo205 human colon carcinoma cells have been described before .
Construction of the TNF-Selectokine and prodrug expression vectors
The TNF-Selectokine expression plasmid pDB1 is based on the eukaryotic expression vector pG1D105 (kindly provided by J Park, Boehringer Ingelheim Pharma KG, Biberach, Germany) containing the TNF-Selectokine cassette coding for: a 19 aa long secretory leader sequence; the FAP specific scFvMO36 (Brooks et al., 2001) ; a trimerization domain comprised of aa 110 -139 of chicken Tenascin-C (chTN-C) (Kammerer et al., 1998) ; a 6 aa linker (GTGGGS); a human TNF derivate of the 26 kDa precursor with deletions of aa 1 -57 and 78 -89 (D1-57/78 -89), thus removing the cytoplasmic, the membrane domain and the TACE cleavage site (Black et al., 1997) , respectively. The construct carries a C-terminal myc-and His 6 -tag (Kontermann et al., 1995) for affinity purification. Amino acids 58 -77 of TNF are used as a linker, because these aa are thought to have no secondary structure. Two TNF-Selectokine prodrug expression plasmids pW32 and pW24, based on pDB1, have been constructed. For both constructs, a 25 aa linker (S G M T P R^G S I G A P F G R^G A P F V R^I E G R^), containing a cleavage site for thrombin, tPA, factor VIIa and uPA (in bold letters, cleavage position indicated by^), followed by the extracellular, cysteine rich domains 1 -3 (aa 14 -138) of human TNFR1 (Banner et al., 1993) was inserted between TNF and the myc-His-tag of pDB1. Plasmid pW24 is identical to pW32 in all domains except the scFv module, which is derived from an independent, humanized FAP specific antibody, OS4 (Mersmann et al., 2001) , with similar structural and functional properties as MO36, but differing in that it is not crossreactive with mouse FAP. scFvMO36 and scFvOS4, respectively, were inserted into the expression plasmid already containing the leader sequence and the myc-His 6 tag using the restriction enzymes ApaI/NotI; the chTN-C fragment was PCR amplified (Pwo polymerase, AGS, Heidelberg, Germany) with the primers Tri5 (taaataggggcccacagccaggcggccgcctgtggctgtgcggctgc) and Tri3 (ataaatggtaccctgctcccggagggagga) and inserted with NotI/Acc65I; the linker together with the TNF fragment was inserted with Acc651/ BamHI in front of the myc-His 6 -tag. For construction of the prodrug, the protease sensitive linker was added to the TNFR-fragment by PCR amplification and inserted by Kpn2I/BamHI into pDB1. Sequencing of the PCR amplified fragments showed no point mutations.
Production of the TNF-Selectokine and the TNF-Selectokine Prodrug CHO DG44 cells were stably transfected with the construct pDB1 (TNF-Selectokine) and pW32/pW24 (TNF-Selectokine prodrugs) using lipofectamin (Life Technologies, Karlsruhe, Germany). Production was increased by methotrexate selection up to a concentration of 25 mM. For production 10 5 CHO-cells/ml were grown in cho-s-sfm II supplemented with 25 mM methotrexate for 3 -4 days in a cell culture spinner flask. The proteins were purified from the supernatant via the C-terminal histidine tag by affinity chromatography (IMAC) on Zn 2+ loaded Hi-Trap columns (Pharmacia, Freiburg, Germany).
Characterization of the fusion proteins
SDS -PAGE was performed under standard conditions. Gels were shared with Coomassie Blue. For Western blotting analyses, proteins were transferred to nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany). The membrane was blocked with 2% Tween80, incubated with cmyc specific 9E10 hybridoma supernatant, followed by alkaline phosphatase coupled mouse IgG-Fc specific serum (Sigma, Deisenhofen, Germany) and stained with NBT/BCIP. Size exclusion chromatography on Pharmacia Superdex HR 200(10/30) FPLC column was performed under standard conditions with 0.5 ml/min and PBS as running buffer.
Immuno-fluorescence flow cytometry
All cells were stained for FACS analyses following standard protocols of indirect immunofluorescence. Bound TNFSelectokine and prodrug was detected by c-myc specific 9E10 hybridoma supernatant. In all cases FITC conjugated goat anti-mouse IgG-Fc (Sigma, Deisenhofen, Germany) was used as secondary antibody. Five thousand cells were measured in EPICS-XL (Coulter Germany, Krefeld, Germany).
In vitro activation of the prodrug
The IMAC purified prodrug was activated with a 0.01% Trypsin solution in PBS for 2 min at RT. The reaction was stopped by adding culture medium containing 10% FCS. For proteolytic activation with tPA, the IMAC-purified prodrug was incubated for 36 h at 378C in PBS with 20 mg/ml tPA (Calbiochem-Novabiochem, Bad Soden, Germany).
Cytotoxicity assays
The bioactivity of TNF-Selectokine, prodrug and recombinant human TNF as a positive control (kind gift of D Ma¨nnel, Regensburg, Germany) was determined in a standard cytotoxicity assay with KYM-1 or HT1080 fibrosarcoma cells, in the latter case cycloheximide was added at final concentration of 2.5 mg/ml. Cells were plated in flat bottom microtiter plates at a density of 2610 4 cells/well and incubated overnight for cell adherence before test reagents were added. After incubation with reagents for 16 h, cell viability of Kym-1 was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, 50 mg/well, Sigma, Deisenhofen, Germany) staining for 2 h at 378C. The supernatant was removed and cells lysed with Isopropanol/0.04N HCl. HT1080 viability was determined by crystal violet staining (0.5% in 20% methanol). For both stainings absorption was measured at 550 nm. Values of untreated cells was set as 100% viability, the absorption of unstained control cells as 0%. Assays were set up in quadruplicates.
For coculture assays the target cells KYM-1 and Colo205, respectively, were added to FAP-positive, TNF-Selectokine presenting HT1080/#33 cells (2610 4 ), seeded in microtiter plates the day before. FAP-negative HT1080 served as controls. The confluent monolayers were then incubated with serial dilutions of the indicated reagents for 1 h at 378C, washed once with PBS, and were used directly or were fixed with 2% formaldehyde for 10 min at 378C followed by three washing cycles with PBS before KYM-1 cells (40 000) or Colo205 (20 000) were added to each well. The viability of the cells was measured after incubation for 16 (Kym-1) or 48 (Colo205) h as described above. For the activation of the prodrug in cell bound form, the assay was performed essentially in the same way but the prodrug was activated by trypsin treatment of prodrug decorated cells (0.01% w/v in PBS for 2 min at RT) before fixation of cells with formaldehyde. In a second assay, HT1080 and HT1080#33 were preincubated with DB1 in suspension, washed, fixed as above and plated at a 1 : 1 ratio with Colo205 target cells (2610 4 /well) in V-shaped microtiter plates. DB1 was then added to the coculture at the same concentrations as used during preincubation of HT1080 to identify a potential targeting independent action of soluble TNF-Selectokine on Colo205. Viability was determined after 48 h as described above.
Abbreviations aa, amino acid; FACS, fluorescence activated cell sorter; FAP, fibroblast activation protein; FCS, fetal calf serum; dhfr, dihydrofolate reductase; mAb, monoclonal antibody; MTD, maximum tolerated dose; scFv, single-chain fragment of immunoglobulin variable regions; TNF, tumor necrosis factor; memTNF, membrane form of TNF; TNFR, TNFReceptor; tPA, tissue-type plasminogen activator; uPA, urokinase-type plasminogen activator.
